When it comes to migraine treatments, one-size-fits-all does not apply. Fortunately, a new option is on the horizon. Atzumi — a dihydroergotamine (DHE) nasal powder — received approval from the U.S.

Real-world data suggest GLP-1 receptor agonists may reduce emergency care visits and the need for additional migraine treatments in adults with chronic migraine.

Talk about a surprise perk. Numerous additional benefits of GLP-1 weight loss drugs like Ozempic continue to be discovered, ...

Recent research shows that GLP-1s may help reduce the need for emergency care in those with chronic migraine. This research ...

A new study finds that GLP-1 drugs may help to stabilize chronic migraines, with patients seeing fewer ER visits and less ...

Doctors break it down.

As CGRP-targeted therapies move into wider use, new data are beginning to clarify their role in special populations, the value of switching agents when one fails, and their long-term vascular safety.

When you buy through links on our articles, Future and its syndication partners may earn a commission. A GLP-1 agonist, the same class of drugs as Ozempic, may treat migraine, a study finds. | Credit: ...

NICE has recommended new migraine pills, giving thousands faster relief from attacks and transforming treatment ...

For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such ...

Migraine is a complex neurological disease that affects about 1 billion people globally. It is associated with a variety of symptoms that can vary widely from person to person, and even from attack to ...